Jul 28, 2022 8:00am EDT Sapience Therapeutics to Participate Virtually in Upcoming August Investor Conferences
Jun 03, 2022 8:00am EDT Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors
Jun 02, 2022 8:00am EDT Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)
May 31, 2022 8:00am EDT Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions
May 12, 2022 8:04am EDT Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022
May 03, 2022 8:00am EDT Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma
Apr 11, 2022 10:00am EDT Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways
Mar 31, 2022 8:00am EDT Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
Mar 15, 2022 4:05pm EDT Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
Mar 09, 2022 8:00am EST Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
